Tumor-targeted nanomedicines for cancer theranostics

Alexandra G. Arranja, Vertika Pathak, Twan Lammers*, Yang Shi (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

176 Citations (Scopus)
671 Downloads (Pure)


Chemotherapeutic drugs have multiple drawbacks, including severe side effects and suboptimal therapeutic efficacy. Nanomedicines assist in improving the biodistribution and target accumulation of chemotherapeutic drugs, and are therefore able to enhance the balance between efficacy and toxicity. Multiple types of nanomedicines have been evaluated over the years, including liposomes, polymer-drug conjugates and polymeric micelles, which rely on strategies such as passive targeting, active targeting and triggered release for improved tumor-directed drug delivery. Based on the notion that tumors and metastases are highly heterogeneous, it is important to integrate imaging properties in nanomedicine formulations in order to enable non-invasive and quantitative assessment of targeting efficiency. By allowing for patient pre-selection, such next generation nanotheranostics are useful for facilitating clinical translation and personalizing nanomedicine treatments.

Original languageEnglish
Pages (from-to)87-95
Number of pages9
JournalPharmacological Research
Publication statusPublished - 1 Jan 2017


  • Clinical translation
  • Imaging
  • Nanomedicine
  • Theranostics
  • Tumor targeting


Dive into the research topics of 'Tumor-targeted nanomedicines for cancer theranostics'. Together they form a unique fingerprint.

Cite this